1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Θετικών Επιστημών
  4. Τμήμα Χημείας
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/7984
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTsimihodimos, V.en
dc.contributor.authorKakafika, A.en
dc.contributor.authorTambaki, A. P.en
dc.contributor.authorBairaktari, E.en
dc.contributor.authorChapman, M. J.en
dc.contributor.authorElisaf, M.en
dc.contributor.authorTselepis, A. D.en
dc.date.accessioned2015-11-24T16:37:58Z-
dc.date.available2015-11-24T16:37:58Z-
dc.identifier.issn0022-2275-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/7984-
dc.rightsDefault Licence-
dc.subjecthyperlipidemiaen
dc.subjectplatelet-activating factor-acetylhydrolaseen
dc.subjectparaoxonaseen
dc.subjectplatelet-activating-factoren
dc.subjectfactor-acetylhydrolase activityen
dc.subjectlow-density-lipoproteinen
dc.subjecthuman plasmaen
dc.subjectphospholipase a(2)en
dc.subjectapolipoprotein-een
dc.subjectcoronary hearten
dc.subjectldlen
dc.subjectparaoxonaseen
dc.subjectdiseaseen
dc.titleFenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteinsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primaryDOI 10.1194/jlr.M200452-JLR200-
heal.identifier.secondary<Go to ISI>://000183031000008-
heal.identifier.secondaryhttp://www.jlr.org/content/44/5/927.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.publicationDate2003-
heal.abstractHuman plasma platelet-activating factor acetylhydrolase (PAF-AH) is an enzyme associated mainly with the apolipoprotein B (apoB)-containing lipoproteins and primarily with LDL. A small proportion of enzymatic activity is also associated with HDL. Plasma paraoxonase 1 (PON1) Is an esterase exclusively associated with HDL. The effect of fenofibrate on PAF-AH and PON1 activities in patients with dyslipidemias of Types IIA, IIB, and IV were studied. Fenofibrate reduced plasma PAF-AH activity in all patient groups. In Type IIA patients, this reduction was mainly due to a fall in enzyme activity associated with the dense LDL subspecies, whereas in Type IIB and Type IV patients, it was due to the decrease in PAF-AH activity associated with both the VLDL+IDL and dense LDL subspecies. Drug therapy in Type IIB and Type IV patients significantly increased the HDL-associated PAF-AH activity due to the increase in enzyme activity associated with the HDL-3c subfraction. Fenofibrate did not affect serum PON1 activities toward paraoxon and phenylacetate in either patient group. The fenofibrate-induced elevation of HDL-associated PAF-AH activity in dyslipidemic patients of Type IIB and Type IV, as well as the reduction in enzyme activity associated with atherogenic apoB-containing lipoproteins in all patient groups, may represent a new and important antiatherogenic effect of this potent lipid-modulating agent.en
heal.publisherLipid Research, Inc.en
heal.journalNameJournal of Lipid Researchen
heal.journalTypepeer reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ

Show simple item record
Files in This Item:
File Description SizeFormat 
Tsimihodimos-2003-Fenofibrate induces.pdf208.71 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons